Merck Animal Health has received FDA approval for NUMELVI™ (atinvicitinib tablets), the first and only second-generation JAK inhibitor indicated for control of pruritus associated with allergic dermatitis in dogs six months of age and older.
Merck reported full-year 2025 worldwide sales of $65.0 billion, supported by strong performance in oncology and animal health and growing contributions from newer product launches.
Mexico’s SADER approved Merck Animal Health’s EXZOLT® 5% Pour-On (fluralaner 50 mg/mL) for the prevention and treatment of New World Screwworm larvae, strengthening cattle protection and supporting Mexico’s beef industry.
Merck’s Animal Health segment grew 9% to $1.6B in the third quarter of 2025, driven by strong livestock demand; companion animal dipped 2% amid parasiticide competition and fewer vet visits.